<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article112</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/CORONA" style="display:block; margin-bottom:10px;">CORONA Original</a></li>
<h2><strong>CORONA</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Rosuvastatin in Older Patients with Systolic Heart Failure". The New England Journal of Medicine. 2007. 357(22):2248-2261. PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
<br/>
1. Clinical Question<br/>
2. Bottom Line<br/>
3. Major Points<br/>
4. Guidelines<br/>
5. Design<br/>
6. Population<br/>
   6.1 Inclusion Criteria<br/>
   6.2 Exclusion Criteria<br/>
   6.3 Baseline Characteristics<br/>
7. Interventions<br/>
8. Outcomes<br/>
   8.1 Primary Outcome<br/>
   8.2 Secondary Outcomes<br/>
9. Criticisms<br/>
10. Funding<br/>
11. Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
<br/>
In older patients with systolic heart failure, does the addition of rosuvastatin to standard heart failure therapy affect cardiovascular outcomes?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
<br/>
In older patients with systolic heart failure, rosuvastatin did not reduce the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke despite improving lipid profiles.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
<br/>
This study assessed the impact of statin therapy on cardiovascular outcomes in a population with systolic heart failure, where acute coronary events are less common. The results indicated no reductions in primary composite outcome or total mortality but did show a reduction in cardiovascular hospitalizations.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
<br/>
As of the most recent guidelines, specific recommendations regarding statin therapy in systolic heart failure have not been universally established.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
<br/>
- Multicenter, double-blind, randomized, placebo-controlled trial<br/>
- N=5,011 patients with systolic heart failure, at least 60 years old<br/>
- Rosuvastatin (10 mg daily) vs. placebo<br/>
- Median follow-up: 32.8 months<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
<br/>
Inclusion Criteria<br/>
<br/>
- Age ≥60 years<br/>
- NYHA class II, III, or IV ischemic systolic heart failure<br/>
- Ejection fraction ≤40% (≤35% if NYHA class II)<br/>
<br/>
Exclusion Criteria<br/>
<br/>
- Previous statin-induced myopathy<br/>
- Decompensated heart failure<br/>
- Recent myocardial infarction, unstable angina, or stroke<br/>
- Recent or planned revascularization or device implantation<br/>
- Significant noncardiac comorbidity<br/>
<br/>
Baseline Characteristics<br/>
<br/>
- Well-matched between groups<br/>
- Mean age 73 years<br/>
- High rates of comorbid conditions such as hypertension and diabetes<br/>
- Majority on comprehensive heart failure medication regimens<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
<br/>
- Rosuvastatin 10 mg or matching placebo, once daily<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
<br/>
Primary Outcome<br/>
<br/>
- No significant reduction in the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke with rosuvastatin<br/>
<br/>
Secondary Outcomes<br/>
<br/>
- No significant reduction in all-cause mortality<br/>
- Fewer hospitalizations for cardiovascular causes with rosuvastatin<br/>
- No impact on NYHA functional class or patient well-being<br/>
- Rosuvastatin demonstrated a favorable safety profile<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
<br/>
- Patients were typically on extensive background heart failure therapies, which might have influenced the lack of observed benefit.<br/>
- The population may not represent all patients with systolic heart failure, such as those with nonischemic heart failure or those with a preserved ejection fraction.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
<br/>
- Supported by AstraZeneca.<br/>
- Multiple authors reported personal fees from AstraZeneca and other disclosures.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
<br/>
- Full article on The New England Journal of Medicine's website.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
